Ana Lledo Delgado, MD
Associate Research ScientistCards
About
Research
Publications
2025
Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long S, McNamara J, Nguyen H, Serti E, Sumida T, Herold K. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes. Nature Communications 2025, 16: 5033. PMID: 40447640, PMCID: PMC12125364, DOI: 10.1038/s41467-025-60276-5.Peer-Reviewed Original ResearchConceptsCD8+ T cellsEBV-seropositive individualsType 1 diabetesT cellsImmune cellsAntigen-specific CD8+ T cellsDiagnosis of type 1 diabetesEBV-seronegative patientsEBV-seropositive patientsT cell activation pathwaysRegulatory T cellsAnti-CD3 mAbInnate immune cellsPeripheral blood cellsT cell receptorProgression of diseaseContext of type 1 diabetesImpaired signaling pathwaysTeplizumabClinical trialsLatent EBVBlood cellsSingle cell transcriptomicsModulate progressionMTOR signaling
2024
Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes
Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley P, Long S, Liu C, Koroleva G, Martins A, Tsang J, Herold K. Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes. Journal Of Clinical Investigation 2024, 134: e177492. PMID: 39137044, PMCID: PMC11405034, DOI: 10.1172/jci177492.Peer-Reviewed Original ResearchCD8+ T cellsAutoreactive T cellsT cellsType 1 diabetesPeripheral blood CD8+ T cellsBlood CD8+ T cellsExpansion of autoreactive T cellsOperational toleranceExpression of CD127Progression of type 1 diabetesAnti-CD3 mAbAntigen-specific repertoireT cell receptorAt-risk patientsAnalysis of study participantsStudy participantsIL7R expressionTeplizumab groupCD8+Placebo groupCD4+Clinical respondersFree intervalTeplizumabReduced expression of genesReshaping immune cells and the antigen-specific repertoire by anti-CD3 mAb teplizumab in Type 1 diabetes
lledo delgado A, Preston-Hurlburt P, Currie S, Clark P, Herold K. Reshaping immune cells and the antigen-specific repertoire by anti-CD3 mAb teplizumab in Type 1 diabetes. The Journal Of Immunology 2024, 212: 0958_5059-0958_5059. DOI: 10.4049/jimmunol.212.supp.0958.5059.Peer-Reviewed Original ResearchCD8+ T cellsT cellsType 1 diabetesCD8+ T cell exhaustionAutoreactive CD8+ T cellsT cell exhaustionT cell changesCD8+ cellsProgression of type 1 diabetesAnti-CD3 mAbAntigen-specific repertoireAt-risk patientsCD8+CD4+Eomes expressionPeripheral bloodTeplizumabImmune cellsImmune regulationT1D diagnosisCD8Operational toleranceDelay progressionMonthsIndividuals at-risk
2022
Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities
Retuerto M, Lledó A, Fernandez-Varas B, Guerrero-López R, Usategui A, Lalueza A, García-García R, Mancebo E, Paz-Artal E, Sastre L, Perona R, Pablos J. Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities. Immunity & Ageing 2022, 19: 38. PMID: 35996190, PMCID: PMC9394033, DOI: 10.1186/s12979-022-00294-9.Peer-Reviewed Original ResearchZ-scoreClinical outcomesCOVID-19 outcomesPost-COVID-19 manifestationsAssociated with COVID-19 hospitalizationLung abnormalitiesAssociated with shorter TLTelomere shorteningTelomere lengthPCR-confirmed COVID-19Baseline TLHospital clinical outcomesCOVID-19 hospitalizationQuantitative-PCRSevere COVID-19Shorter leukocyte telomere lengthShorter TLCOVID-19 manifestationsCOVID-19 patientsPatient 1Associated with worse COVID-19 outcomesRadiographic abnormalitiesLeukocyte telomere lengthShorter telomere lengthPatients
2021
SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy
Lledó A, Retuerto M, Almendro-Vázquez P, Fernández-Ruiz M, Galindo M, Laguna-Goya R, Paz-Artal E, Lalueza A, Aguado J, Pablos J. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy. Seminars In Arthritis And Rheumatism 2021, 51: 1258-1262. PMID: 34775160, PMCID: PMC8572149, DOI: 10.1016/j.semarthrit.2021.10.006.Peer-Reviewed Original ResearchConceptsT cell responsesImmunosuppressive therapyRheumatic diseasesSARS-CoV-2 antigensDevelopment of T cell responsesSARS-CoV-2-specific T cell responsesSARS-CoV-2Synthetic disease-modifying anti-rheumatic drugsEffects of immunosuppressive therapyDisease-modifying anti-rheumatic drugsImmune-mediated rheumatic diseasesPeripheral blood mononuclear cellsIL-17 inhibitorsAntigen-specific responsesCohort of patientsTNF-a inhibitorsAnti-rheumatic drugsBlood mononuclear cellsAutoimmune rheumatic diseasesRheumatic disease patientsCOVID-19 recoveryImmune disturbancesT cellsAdult patientsIL-17
2020
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena Vázquez N, Mera Varela A, Retuerto M, Seijas-Lopez A, RIER investigators group.. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020, 79: 1170-1173. PMID: 32532753, DOI: 10.1136/annrheumdis-2020-217763.Peer-Reviewed Original ResearchClinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Pablos J, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay M, Martinez-Lopez D, Castrejón I, Alvaro-Gracia J, Fernández D, Mera-Varela A, Manrique-Arija S, Vázquez N, Fernandez-Nebro A, group R, Aguirre R, Seijas-López Á, Blanco F, Carreira P, Martín-López M, Gonzalez A, Puig-Kröger A, Salas L. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Annals Of The Rheumatic Diseases 2020, 79: 1544-1549. PMID: 32796045, DOI: 10.1136/annrheumdis-2020-218296.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAge FactorsAgedAlanineAntiviral AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusCardiovascular DiseasesCase-Control StudiesCohort StudiesComorbidityConnective Tissue DiseasesCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug CombinationsFemaleGlucocorticoidsHospitalizationHumansHydroxychloroquineImmunosuppressive AgentsLogistic ModelsLopinavirLupus Erythematosus, SystemicMaleMiddle AgedObesityPandemicsPneumonia, ViralPolymyalgia RheumaticaPrognosisRheumatic DiseasesRisk FactorsRitonavirSARS-CoV-2Severity of Illness IndexSex FactorsSjogren's SyndromeSpondylarthropathiesConceptsConnective tissue diseaseSevere COVID-19Associated with severe COVID-19Inflammatory rheumatic diseasesMale sexRheumatic diseasesInflammatory arthritisClinical outcomesCohort studyHospitalised patientsIntensive care unit admissionChronic inflammatory rheumatic diseasesOutcomes of hospitalised patientsPotential prognostic variablesCohort of patientsNon-rheumatic controlsNon-rheumatic patientsComparative cohort studyAutoimmune rheumatic diseasesRisk of severe COVID-19Matched Cohort StudyChronic inflammatory arthritisLogistic regression analysisPotential risk factorsImmunosuppressive therapy
2018
MA11.06 Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression
Ajona D, Pajares M, Freire J, Gomez-Roman J, Martinez-Terroba E, Ortiz-Espinosa S, Lledo A, Arenas-Lazaro E, Agorreta J, Lecanda F, Montuenga L, Pio R. MA11.06 Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression. Journal Of Thoracic Oncology 2018, 13: s394. DOI: 10.1016/j.jtho.2018.08.407.Peer-Reviewed Original Research